Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Latest From Andrew McConaghie
Having achieved a turnaround in its R&D and commercial fortunes, AstraZeneca’s hopes the opening of a new research center will herald its next wave of novel therapies.
The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.
After an expensive and protracted construction, AstraZeneca hopes its Cambridge research center will help foster collaboration and extend its run of R&D success.
Merck & Co. is looking to compete in the burgeoning long-acting HIV market, but a safety halt to a Phase II trial could disrupt those plans.
While Democrat politicians - and most voters- want to see drug pricing negotiations introduced in the US for the first time, pharma leaders believe a deal on out of pocket costs will be agreed instead.
While Democratic politicians – and most voters – want to see drug pricing negotiations introduced in the US for the first time, pharma leaders still believe a deal on out of pocket costs will be agreed instead.